We report the first case of chronic myeloid leukemia (CML) in a patient with multiple sclerosis (MS) diagnosed within two years of receiving mitoxantrone therapy. Previously only acute forms of leukemia particularly acute promyelocytic leukemia (APL) have been associated with mitoxantrone treatment in MS. This underscores the need for only using mitoxantrone in severe treatment-unresponsive cas...

BACKGROUND To manage relapsing-remitting multiple sclerosis (MS) in the course of acute exacerbations, methylprednisolone (MP) (Medrol or Solu-Medrol), has the ability to lock the injured blood-brain barrier and decrease irritation in the central nervous system. The aim of this preliminary study was to investigate the frequency and time interval related to MP pulse therapy in patients with MS. ...

background: complete atrioventricular block (av block) is a serious complication of slow pathway ablation therapy in the treatment of atrioventricular nodal re-entrant tachycardia (avnrt).   the present study was aimed at determining whether the electroanatomical pace mapping of koch’s triangle could significantly improve the safety, efficiency, and efficacy of selective slow pathway ablation i...

This article provides a behavioral formulation and treatment plan for the case of Ms. S. Given the complexity of Ms. S and the status of current research, interventions proposed emphasize empirically supported principles of change over any specific protocol. This particular behavioral approach incorporates aspects of dialectical behavior therapy and functional analytic psychotherapy in addition...

1353 Ocular Changes in Patients With Mucopolysaccharidosis I Receiving Enzyme Replacement Therapy: A 4-Year Experience Susanne Pitz, MD, PhD; Olufunmilola Ogun, FWACS; Manal Bajbouj, MD; Laila Arash, MD; Gudrun Schulze-Frenking, MD; Michael Beck, MD, PhD 1357 Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration Ziad F. Bashshur, MD; Alexa...

industry continues to support research to improve efficacy and tolerance, care providers must recognize that the impact of disease modifying therapy on the MS population will also depend on our ability to optimize use. We have all heard the quote from former US Surgeon General C. Everett Koop that ‘drugs don’t work if you don’t take them’ however we must also recognize that the impact of treatm...

Interferon beta (IFNbeta) therapy for multiple sclerosis (MS) is associated with a potential for the development of neutralising antibodies (NAbs) that negatively affect therapy. Several factors influence the development of NAbs, such as lack of complete sequence homology with the endogenous IFNbeta sequence, frequency of administration, level of dose and formulation of IFNbeta. Taken together,...

Pediatric multiple sclerosis (MS) comprises 2-5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which is resistant to treatment with these therapies. Natalizumab is a therapy which, although associat...

Finglimod, a sphingosine 1-phosphate receptor modulator, is the first orally administered therapy approved for prophylaxis in multiple sclerosis (MS). Several reports in the last two years suggested that it might be associated with severe augmentation of disease activity upon initiation or discontinuation of therapy. We present an MS patient who developed a giant cavitating brain lesion under f...

MS is a chronic, increasingly disabling disease whose long-term outcomes determine the key social, medical and economic impact of this disease. Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are prescribed to delay disease progression and to protect a patient's functional capability. The concepts of escalation and induction immunotherapy in MS represent different therapeutic str...